Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with turner syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 12, 2002, Pages 5442-5448

  Van Pareren, Yvonne K ^a   De Muinck Keizer Schrama, Sabine M P F ^a   Stijnen, Theo ^b   Sas, Theo C J ^a   Drop, Stenvert L S ^a   Jansen, M ^c   Otten, B J ^d   Hoorweg Nijman, J J G ^e   Vulsma, T ^f   Stokvis, J ^g   Rouwe C W ^h   Reeser, H M ⁱ   Gerver, W J ^j   Gosen, J J ^k   Rongen Westerlaken, C ^l  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f EMMA CHILDREN S HOSPITAL   (Netherlands)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF GRONINGEN   (Netherlands)

ⁱ JULIANA CHILDREN S HOSPITAL   (Netherlands)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^k RIJNLAND HOSPITAL   (Netherlands)

^l CANISIUS WILHELMINA HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CHOLESTEROL; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHILD; CLINICAL TRIAL; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RISK FACTOR; SHORT STATURE; TREATMENT OUTCOME; TURNER SYNDROME; WEIGHT GAIN;

BLOOD PRESSURE; BODY MASS INDEX; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; RISK FACTORS; TURNER SYNDROME;

EID: 0036920811     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020789     Document Type: Article

References (41)

1. Wit JM, Massarano AA, Kamp GA, Hindmarsh PC, van Es A, Brook CG, Preece MA, Matthews DR 1992 Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinol (Copenh) 127:7-12
2. Carel JC, Mathivon L, Gendrel C, Ducret JP, Chaussain JL 1998 Near normalization of final height with adapted doses of growth hormone in Turner's syndrome. J Clin Endocrinol Metab 83:1462-1466
3. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C, Drop SL 1999 Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: Results of a randomized dose-response trial. J Clin Endocrinol Metab 84:4607-4612
4. van Teunenbroek A, de Muinck Keizer-Schrama SM, Aanstoot HJ, Stijnen T, Hoogerbrugge N, Drop SL 1999 Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Dutch Working Group on Growth Hormone. Metabolism 48:7-14
5. Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, Price DA 2000 Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 355:610-613
6. Price WH, Clayton JF, Collyer S, De Mey R, Wilson J 1986 Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. J Epidemiol Community Health 40:97-102
7. Gravholt CH, Juul S, Naeraa RW, Hansen J 1998 Morbidity in Turner syndrome. J Clin Epidemiol 51:147-158
8. Ross JL, Feuillan P, Long LM, Kowal K, Kushner H, Cutler Jr GB 1995 Lipid abnormalities in Turner syndrome. J Pediatr 126:242-245
9. Gravholt CH, Naeraa RW, Nyholm B, Gerdes LU, Christiansen E, Schmitz O, Christiansen JS 1998 Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement. Diabetes Care 21:1062-1070
10. Elsheikh M, Conway GS 1998 The impact of obesity on cardiovascular risk factors in Turner's syndrome. Clin Endocrinol (Oxf) 49:447-450
11. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Aanstoot HJ, Drop SL 2000 Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab 85:769-775
12. 1997 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183-1197
13. Potau N, Ibanez L, Rique S, Carrascosa A 1997 Pubertal changes in insulin secretion and peripheral insulin sensitivity. Horm Res 48:219-226
14. Karlberg J, Albertsson-Wikland K, Naeraa RW, Rongen-Westerlaken C, Wit JM 1992 Reference values for spontaneous growth in Turner girls and its use in estimating treatment effects. In: Hibi I, Takano K, eds. Basic and Clinical Approach to Turner Syndrome: 3rd International Symposium on Turner Syndrome; July 8-10, 1992. Chiba, Japan: Elsevier Science Publishers B. V.; 83-92
15. Roede MJ, van Wieringen JC 1985 Growth diagrams 1980. Netherlands third nation-wide survey. Tijdschr Soc Gezondh 63(Suppl):1-34
16. Task Force on Blood Pressure Control in Children 1987 Report of the second task force on blood pressure control in children national heart, lung, and blood institute, Bethesda, Maryland. Pediatrics 79:1-25
17. Uiterwaal CS, Witteman JC, de Bruijn AM, Hofman A, Grobbee DE 1997 Families and natural history of lipids in childhood: An 18-year follow-up study. Am J Epidemiol 145:777-785
18. Lesage C, Walker J, Landier F, Chatelain P, Chaussain JL, Bougneres PF 1991 Near normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency. J Pediatr 119:29-34
19. Joss EE, Zurbrugg RP, Tonz O, Mullis PE 2000 Effect of growth hormone and oxandrolone treatment on glucose metabolism in Turner syndrome. A longitudinal study. Horm Res 53:1-8
20. Bloch CA, Clemons P, Sperling MA 1987 Puberty decreases insulin sensitivity. J Pediatr 110:481-487
21. Cutfield WS, Bergman RN, Menon RK, Sperling MA 1990 The modified minimal model: Application to measurement of insulin sensitivity in children. J Clin Endocrinol Metab 70:1644-5160
22. Reaven GM, Moore J, Greenfield M 1983 Quantification of insulin secretion and in vivo insulin action in nonobese and moderately obese individuals with normal glucose tolerance. Diabetes 32:600-604
23. Travers SH, Jeffers BW, Bloch CA, Hill JO, Eckel RH 1995 Gender and Tanner stage differences in body composition and insulin sensitivity in early pubertal children. J Clin Endocrinol Metab 80:172-178
24. Caprio S, Boulware S, Diamond M, Sherwin RS, Carpenter TO, Rubin K, Amiel S, Press M, Tamborlane WV 1991 Insulin resistance: An early metabolic defect of Turner's syndrome. J Clin Endocrinol Metab 72:832-836
25. Polychronakos C, Letarte J, Collu R, Ducharme JR 1980 Carbohydrate intolerance in children and adolescents with Turner syndrome. J Pediatr 96:1009-1014
26. Elsheikh M, Bird R, Casadei B, Conway GS, Wass JA 2000 The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner's syndrome. J Clin Endocrinol Metab 85:614-618
27. Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 2001 Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol (Oxf) 54:243-251
28. Nathwani NC, Unwin R, Brook CG, Hindmarsh PC 2000 The influence of renal and cardiovascular abnormalities on blood pressure in Turner syndrome. Clin Endocrinol (Oxf) 52:371-377
29. Price DA, Clayton PE, Crowne EH, Roberts CR 1993 Safety, and efficacy of human growth hormone treatment in girls with Turner syndrome. Horm Res 39:44-48
30. Lanes R, Gunczler P, Palacios A, Villaroel O 1997 Serum lipids, lipoprotein 1p(a), and plasminogen activator inhibitor-1 in patients with Turner's syndrome before and during growth hormone and estrogen therapy. Fertil Steril 68:473-477
31. Saenger P, Attie KM, DiMartino-Nardi J, Fine RN 1996 Carbohydrate metabolism in children receiving growth hormone for 5 years. Chronic renal insufficiency compared with growth hormone deficiency, Turner syndrome, and idiopathic short stature. The Genentech Collaborative Group. Pediatr Nephrol 10:261-263
32. Johannsson G, Albertsson-Wikland K, Bengtsson BA 1999 Discontinuation of growth hormone (GH) treatment: Metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 84:4516-4524
33. Kuromaru R, Kohno H, Ueyama N, Hassan HM, Honda S, Hart T 1998 Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: Gender-specific metabolic effects. J Clin Endocrinol Metab 83:3890-3896
34. Mijatovic V, Kenemans P, Netelenbos JC, Peters-Muller ER, van Kamp GJ, Voetberg GA, van de Weijer PH, van der Mooren MJ 1997 Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women. J Clin Endocrinol Metab 82:3543-3547
35. van Stiphout WA, Hofman A, de Bruijn AM, Valkenburg HA 1985 Distributions and determinants of total and high-density lipoprotein cholesterol in Dutch children and young adults. Prev Med 14:169-180
36. Hickman TB, Briefel RR, Carroll MD, Rifkind BM, Cleeman JI, Maurer KR, Johnson CL 1998 Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: Data from the Third National Health and Nutrition Examination Survey. Prev Med 27:879-890
37. Garden AS, Diver MJ, Fraser WD 1996 Undiagnosed morbidity in adult women with Turner's syndrome. Clin Endocrinol (Oxf) 45:589-593
38. Landin-Wilhelmsen K, Bryman I, Wilhelmsen L 2001 Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. J Clin Endocrinol Metab 86:4166-4170
39. van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A, Effect of discontinuation of GH treatment on risk factors for cardiovascular disease in adolescents born small for gestational age. J Clin Endocrinol Metab, in press
40. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC 2000 Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J 139:272-281
41. Hoffman RP, Vicini P, Sivitz WI, Cobelli C 2000 Pubertal adolescent male-female differences in insulin sensitivity and glucose effectiveness determined by the one compartment minimal model. Pediatr Res. 48:384-388